Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) EPS (Basic) (2016 - 2025)

Avalo Therapeutics filings provide 12 years of EPS (Basic) readings, the most recent being -$0.37 for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 95.35% to -$0.37 in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.73, a 96.02% increase, with the full-year FY2025 number at -$5.84, up 26.45% from a year prior.
  • EPS (Basic) hit -$0.37 in Q4 2025 for Avalo Therapeutics, up from -$2.19 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $117.47 in Q4 2023 to a low of -$1059.6 in Q4 2022.
  • Median EPS (Basic) over the past 5 years was -$2.1 (2021), compared with a mean of -$73.96.
  • The widest YoY moves for EPS (Basic): up 116.27% in 2022, down 15930.41% in 2022.
  • Avalo Therapeutics' EPS (Basic) stood at -$6.61 in 2021, then crashed by 15930.41% to -$1059.6 in 2022, then surged by 111.09% to $117.47 in 2023, then crashed by 106.77% to -$7.95 in 2024, then surged by 95.35% to -$0.37 in 2025.
  • The last three reported values for EPS (Basic) were -$0.37 (Q4 2025), -$2.19 (Q3 2025), and -$1.92 (Q2 2025) per Business Quant data.